Evaluación de la reactividad vascular pulmonar con iloprost inhalado en pacientes con hipertensión arterial pulmonar en la sala de hemodinamia del Hospital Central Militar
Contenido principal del artículo
Resumen
El iloprost nebulizado está indicado para evaluar la va- sorreactividad pulmonar e identificar a los pacientes con hipertensión arterial pulmonar y respuesta al tratamiento con calcioantagonistas.
Detalles del artículo
Sección
Cómo citar
Referencias
Chin KM, Rubin LJ. Pulmonary arterial hypertension. J Am Coll Cardiol. 2008 Apr 22;51(16):1527-1538.
Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009 Oct;30(20):2493-2537.
Badesch DB, Champion HC, Sanchez MA, Hoeper MM, Loyd JE, Manes A, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009 Jun 30;54(1 Suppl):S55-66.
McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009 Apr 28;53(17):1573-619.
Simonneau G, Robbins IM, Beghetti M, Channick RN, Del- croix M, Denton CP, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009 Jun 30;54(1 Suppl):S43-54.
Escribano Subias P, Barberà Mir JA, Suberviola V. Evalua- ción diagnóstica y pronóstica actual de la hipertensión pulmonar. Revista Española de Cardiología. [10.1016/ S0300-8932(10)70121-4]. 2010;63(05):583-596.
Opitz CF, Wensel R, Bettmann M, Schaffarczyk R, Lins- cheid M, Hetzer R, et al. Assessment of the vasodilator response in primary pulmonary hypertension. Comparing prostacyclin and iloprost administered by either infusion or inhalation. Eur Heart J. 2003 Feb;24(4):356-65.
Hoeper MM, Olschewski H, Ghofrani HA, Wilkens H, Winkler J, Borst MM, et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aero- solized iloprost in primary pulmonary hypertension. German PPH study group. J Am Coll Cardiol. 2000 Jan;35(1):176-182.
Campos R RM, Morales JE. Iloprost en hipertensión pul- monar: Renacimiento de un viejo conocido. Neumología y Cirugía de Tórax. 2006;65(3):132 - 145.
Gomberg-Maitland M, Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J. 2008 Apr;31(4):891-901.
Olschewski H. Inhaled iloprost for the treatment of pulmo- nary hypertension. Eur Respir Rev. 2009 Mar;18(111):29- 34.
Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004 Jun 16;43(12 Suppl S):5S-12S.
Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epo- prostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996 Feb 1;334(5):296-301.
Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002 Aug 21;40(4):780-788.